about
Institutional shared resources and translational cancer researchDrug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV InfectionSurgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational StudiesThe evolving scenario of non-AIDS-defining cancers: challenges and opportunities of careLevels of soluble E-cadherin in breast, gastric, and colorectal cancersQuantification of Hepatitis C Virus (HCV) in Liver Specimens and Sera from Patients with Human Immunodeficiency Virus Coinfection by Using the Versant HCV RNA 3.0 (Branched DNA-Based) DNA AssayMicroenvironmental abnormalities induced by viral cooperation: Impact on lymphomagenesisAn effective multisource informed consent procedure for research and clinical practice: an observational study of patient understanding and awareness of their roles as research stakeholders in a cancer biobankA pilot project of a cancer patient library in Italy: results of a customer-satisfaction survey and its products.MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer.Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey.Cross-cultural validation of health literacy measurement tools in Italian oncology patientsTime trends of cancer incidence in Setif, Algeria, 1986-2010: an observational study.Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjectsCarcinogenic viruses and solid cancers without sufficient evidence of causal association.KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies.Autograft HIV-DNA load predicts HIV-1 peripheral reservoir after stem cell transplantation for AIDS-related lymphoma patients.Report from the OECI Oncology Days 2014Identification and characterization of CDH1 germline variants in sporadic gastric cancer patients and in individuals at risk of gastric cancer.γ-Herpesvirus load as surrogate marker of early death in HIV-1 lymphoma patients submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation.Differential proteomics of Helicobacter pylori associated with autoimmune atrophic gastritisGenetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.Pharmacovigilance in oncology: evaluation of current practice and future perspectives.Risk factors for early mortality after AIDS in the cART era: A population-based cohort study in ItalyHigh serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.Making patient centered care a reality: a survey of patient educational programs in Italian Cancer Research and Care Institutes.Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicityTracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.Alliance Against Cancer, the network of Italian cancer centers bridging research and careRole of HIV-1 matrix protein p17 variants in lymphoma pathogenesis.Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcomaJoint Nordic prospective study on human herpesvirus 8 and multiple myeloma riskA prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myelomaPatient-Centered Cancer Care Programs in Italy: Benchmarking Global Patient Education Initiatives.The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers.Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Web Conversations About Complementary and Alternative Medicines and Cancer: Content and Sentiment Analysis.Novel virally targeted therapies of EBV-associated tumors.HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.Epstein-Barr virus: novel patented therapeutics.
P50
Q24288943-5727595C-5A89-4B72-A6D1-59B626467360Q26749811-A9A19503-D0A2-4E19-B404-68CEB470288CQ26801141-4D816912-6DB2-4176-A8FC-78BCF0617D45Q26991549-F3FD9318-2FA9-4304-8312-8DF5136C75E2Q27012638-74C3B51A-5D24-4F1E-95FA-C8C7B12F1561Q27477673-3BC56B8A-64B2-4FBD-BE9A-0BCB7CBFA96DQ28082412-1C33F318-D7D5-45EA-B005-EE7B68ED9B5CQ31125290-7E31DE60-69A2-49C2-A9E8-8A9E6A7A1E41Q33267020-3482F239-B31A-43CF-BB75-55C0471B2FF3Q33579778-655FDE0C-38BA-4B7E-AA36-8142906E9DA1Q33648514-27739AA9-BDCD-497D-AC3B-A2D368FDC257Q33814508-45D6D142-7BE5-4034-978F-AF4EAB91582EQ34184859-2242E8A1-FEE6-49BC-888F-82915CE15BF5Q34293966-48298362-F9B9-4C58-BE2F-CF00FFA8AE44Q34320412-88AA4BD7-622A-4B83-B6A9-7873415A9E3CQ34417383-A9C649C5-48C7-4C5C-949C-7324FD773F20Q34869326-30B1FCBD-9249-440A-A30E-6BB381A5067FQ35002560-B1AB7715-4A89-4A3B-B4F1-027BC2167170Q35034978-F969D100-B49A-4956-869A-D3C68179B0B2Q35068371-582006B2-D00B-437E-A98B-C16BC8B129C1Q35084203-11DF3F17-463E-4646-808B-941D92F0A320Q35107234-58158D4E-B22C-4A7F-AA4C-9039D7A2AF49Q35183601-588D5BFA-7D31-419E-9A2D-79419C58A642Q35661739-72FF53E0-14B4-4FD4-AA05-9D31DDE6C3B4Q35674802-900BAB19-F34F-4C2A-B60C-C42AAE83F847Q35724781-D1FA9EFF-4E8E-4CC1-B7AD-D0B0CFAD9C01Q35783467-BA25B98E-BD50-465A-B23F-41F13072EA7CQ35916613-07C98C84-011E-48CA-ABBC-8B4AE078BC65Q36292686-3528B65F-5B97-41EF-B399-41F992295715Q36306025-1913B353-1562-4EF5-B24F-177627E1135AQ36557592-85E7146E-F79A-4DE7-BD24-6BADB822CFAAQ36615392-E9CAF45E-0116-45D0-89B8-D6E812CDD312Q36622176-D8BD719D-87DB-4B07-887A-D17E567973F2Q36798913-4FF5347C-7A69-4AE6-BB99-82CDC8E0075EQ36892139-2B4A046F-158F-4E22-B5B4-15AC65B638A5Q36915163-2B160F2C-A6EA-48EC-9917-6915B20F154CQ37057065-D590B048-DFA0-45C4-B06B-10B635F7A4B0Q37320074-EE3C138A-05C8-4D5B-89DA-F699EC2DA7DFQ37437190-9A91BC07-122F-4C2C-9CD6-39989873CDC1Q37729167-53AD64E7-97F9-4D87-8FDA-F00CAEB0672F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo De Paoli
@ast
Paolo De Paoli
@en
Paolo De Paoli
@es
Paolo De Paoli
@nl
Paolo De Paoli
@sl
type
label
Paolo De Paoli
@ast
Paolo De Paoli
@en
Paolo De Paoli
@es
Paolo De Paoli
@nl
Paolo De Paoli
@sl
prefLabel
Paolo De Paoli
@ast
Paolo De Paoli
@en
Paolo De Paoli
@es
Paolo De Paoli
@nl
Paolo De Paoli
@sl
P106
P1153
7004701424
P21
P31
P496
0000-0002-9502-1781